PubMed Health⌕ Search

Biomedical subjects

S Ruggieri

Publications and source records attributed to S Ruggieri.

At least 145 records · Page 8Linked to original sources
PubMed1977

Biochemical pathogenesis and therapeutical prospectives in degenerative chorea.

In the last few years both neuropathological and neurochemical data have contributed towards a classification of the pathogenesis of degenerative chorea of which Huntington's chorea shows clear evidence of heredity. The role of GABA, DA and Ach in determining chorea seems clear. In 7 patients with degenerative hypotonic-hyperkinetic chorea (the acid metabolites into the cerebrospinal fluid are not available) a neuropharmacological study was conducted. The symptomatology was evaluated both through clinical rating and through phasic and tonic performance tests. The neuropharmacological tests were both acute and chronic. In the acute tests the effect of modification of various neurotransmitters (Ach, DA, NA, GABA) was evaluated. In chronic treatment the effectiveness of haloperidol, PCPA and bromocryptine was evaluated. The results of the acute study were positive both as regards increment of DA (receptors stimulation) and GABA. The chronic study shows any effect of PCPA, positive results both with bromocryptine and with haloperidol. Our results confirm a DA/GABA interaction in the pathogenesis of degenerative chorea.

Acetylcholine↗
PubMed1976

Structural analysis of phosphatidylcholines of Yoshida ascites hepatoma and liver cells from host rats fed a control and an essential fatty acid-deficient diet.

In order to study the effect of a dietetic manipulation on the phospholipid molecular structure of a poorly differentiated tumor, the phosphatidylcholines from Yoshida hepatoma cells (AH130) grown either in essential fatty acid deficient or control rats were analyzed comparatively to those from the host livers. Due to essential fatty acid deficiency, the host rat liver exhibited an increased level of mono-unsaturated 1,2-diacyl-sn-glycero-3-phosphocholines, a reduced level of the species contained linoleic acid, and the substitution of tetra- and polyunsaturated-1,2-diacyl-sn-glycero-3-phosphocholines with equivalent amounts of species containing eicosatrienoic acid. The structural analysis of the phosphatidylcholines from Yoshida hepatoma cells grown either in control or essential fatty acid deficient rats revealed the occurrence of 1-alkyl-2-acyl- together with 1,2-diacyl-sn-glycero-3-phosphocholines. The alkyl chains of ether-linked phosphatidylcholines were mainly constituted by 18 : 1, while the acyl chains were characterized by a high level of linoleic and arachidonic or eicosatrienoic acids. The 1,2-diacyl-sn-glycero-3-phosphocholines of the Yoshida hepatoma cells grown in control rats, when compared to those of the liver, showed a higher level of 1,2-disaturated, an increased proportion of mono-unsaturated and a lower proportion of tetra- and polyunsaturated species. In addition, the hepatoma cells showed the occurrence of high proportions of reverse isomeric and random species, such as 1-oleoyl-2-palmitoyl-, 1,2-dioleoyl-, 1-oleoyl-2-linoleoyl- and 1-linoleoyl-2-oleoyl-sn-glycero-3-phosphocholines, scarcely represented in the liver. Growth of Yoshida hepatoma cells in essential fatty acid deficient rats resulted in :(i) the disappearence of 1,2-diacyl-sn-glycero-3-phosphocholines containing linoleic acid; (ii) the substitution of tetra- and and polyunsaturated 1,2-diacyl-sn-glycero-3-phosphocholines with small quantities of species containing eicosatrienoic acid; (iii) an increase of of monounsaturated species, mainly 1-stearoyl-2-oleoyl- and 1-palmitoyl-2-palmitoleoyl-sn-glycero-3-phosphocholines; (iv) a remarkable increase of 1,2-dioleoyl-sn-1,2-dioleoyl-sn-glycero-3-phosphocholine.

Animals↗
PubMed1976

[Neuroendocrine aspects of Parkinson's disease. Therapeutic/effect of a prolactin inhibitor].

On the basis of a reassessment of the aetiopathogenetic problem and the neuroendocrine implications, the therapeutic effectiveness of a prolactin inhibitor, 2-alpha-Br-ergocryptine (CB 154), in Parkinson's disease is assessed. Five patients were treated for a total of two weeks using doses between 10 and 15 mg/die. CB 154 was found to act as a dopaminergic receptor agonist at nigro-striatal level, considerably improving tremor and rigidity and to a lesser extent bradykinesia and total disability.

Aged↗
PubMed1976

Absence of relationships between L-dopa plasma levels and therapeutic effect in Parkinson's disease treated with L-dopa.

The plasma concentration of dopa was studied in 15 parkinsonian patients after a single administration of L-dopa. The study was undertaken in order to determine if correlation between plasma dopa concentration and clinical performance as a result of the tests carried out before and after a single dose of dopa, was present. Our data confirm the absolute absence of correlation between dopa levels in plasma and clinical improvement during long-term treatment. Moreover, clinical responses to the performance tests were not related to the concentration of circulating L-dopa in the plasma. Therefore dopa levels cannot be useful in clinical practice but only for the prevention of too high concentrations of plasma L-dopa which often cause a few side-effects.

Administration, Oral↗
PubMed1976

Effect of essential fatty acid deficiency on the lipid composition of the Yoshida ascites hepatoma (AH 130) and of the liver and blood plasma from host and normal rats.

In order to study the response of a poorly differentiated tumor to nutritional manipulation, the Yoshida ascites hepatoma (AH 130) was grown in rats fed an essential fatty acid (EFA)-deficient diet and in rats fed a control diet. Hepatomas, livers, and blood plasma from host rats and normal rats were studied as to the effects of EFA deficiency on the lipid composition. Normal rats fed an EFA-deficient diet showed an increased concentration of triglycerides and cholesteryl esters in the liver and a reduced level of total phospholipids in plasma. Host rats fed the EFA-deficient diet showed a lower concentration of triglycerides in the liver when compared with the host rats fed a control diet. In addition, EFA-deficient host rats had reduced levels of plasma free fatty acids and triglycerides. These latter were markedly high in host rats under normal dietetic conditions. As compared to the livers of either host rats or normal rats fed the control diet, the Yoshida hepatoma cells had a lower content of total phospholipids and free fatty acids as well as a higher level of free cholesterol; they also showed a typical fatty acid pattern in their phospholipids. The main characteristics of this pattern were a high content of oleic and palmitoleic acids and a low level of C20 and C22 polyunsaturated fatty acids. Exposure of Yoshida hepatoma cells to an EFA-deficient environment resulted in a decrease in the concentration of total phospholipids and free fatty acids and in changes in the fatty acid composition similar to those observed in the livers of normal and host rats. These changes suggest that, under the experimental conditions used, the Yoshida hepatoma cells are responsive to EFA deficiency.

Animals↗